Biomarker landscape

The cardiovascular biomarker landscape is rapidly changing from mono marker assays to multimarker panels. The discovery of microRNAs as a new class of circulating biomarkers and the introduction of game-changing technology platforms allow full cardiovascular risk profiling by simultaneously measuring a combined miRNA and protein multi-marker panel.
Read more

Unmet need in heart failure

The clinical effectiveness of the current generation of heart failure biomarkers is limited by the need to repeatedly measure multiple individual markers in order to generate a full risk profile of a HF patient. The classical HF protein markers either have diagnostic or prognostic properties, while measuring multiple protein biomarkers is time-consuming and expensive since costs are additive for each marker.
Read more

Market potential

The annual global market for the brain natriuretic peptide assays (BNP, NT-proBNP) assays is the fastest growing segment of the cardiac biomarker market. Sales reached the $1 billion figure in 2013 and are further projected to reach close to $2 billion in 2017. A novel cost-effective multi-marker IVD test showing improved sensitivity and specificity for the diagnosis and prognosis of heart failure has a major opportunity to capture a substantial part of the cardiac biomarker market. 

Read more

Bookmark and Share